A detailed history of Picton Mahoney Asset Management transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Picton Mahoney Asset Management holds 293 shares of CRNX stock, worth $9,827. This represents 0.0% of its overall portfolio holdings.

Number of Shares
293
Holding current value
$9,827
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Apr 02, 2025

BUY
$50.66 - $60.69 $14,843 - $17,782
293 New
293 $16,000

Others Institutions Holding CRNX

About Crinetics Pharmaceuticals, Inc.


  • Ticker CRNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,752,800
  • Market Cap $1.8B
  • Description
  • Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...
More about CRNX
Track This Portfolio

Track Picton Mahoney Asset Management Portfolio

Follow Picton Mahoney Asset Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Picton Mahoney Asset Management, based on Form 13F filings with the SEC.

News

Stay updated on Picton Mahoney Asset Management with notifications on news.